The design and development of an immunosuppressive drug, mycophenolate mofetil

@article{Allison2004TheDA,
  title={The design and development of an immunosuppressive drug, mycophenolate mofetil},
  author={Anthony C. Allison and Elsie M. Eugui},
  journal={Springer Seminars in Immunopathology},
  year={2004},
  volume={14},
  pages={353-380}
}
Immunosuppressive agents have traditionally been identified in two ways. Some drugs developed for cancer chemotherapy were incidentally found to have immunosuppressive activity (cyclophosphamide, methotrexate, azathioprine), whereas screening of fermentation products revealed the immunosuppressive activity of cyclosporins, FK 506 and rapamycin. Establishing the mode of action of these compounds lagged behind the demonstration of their immunosuppressive activity, and information on this subject… Expand
Advances in immunosuppressive therapy.
TLDR
Significant benefit has been found when interstitial lung disease due to scleroderma is treated with cyclophosphamide, representing the first evidence that immunosuppressive drugs are efficacious in rheumatic disease-associated interstitial fibrosis and provides a rationale for developing therapeutic regimens that optimize efficacy and safety. Expand
Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability
TLDR
The most important side effects under MMF include gastrointestinal disorders, of which the underlying mechanisms are not yet fully understood, but seem to be complex and related to both effects of mycophenolic acid and its acyl glucuronide, as well as to decreased -immunity due to general immunosuppression after transplantation. Expand
Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them?
TLDR
Individualizing the prescription and targets of MMF according to immunologic risk, global immunosuppression, and post-transplant period, as for other Immunosuppressants, is open to discussion and may be beneficial. Expand
Therapeutic monitoring of immunosuppressant drugs. Where are we?
  • P. Wallemacq
  • Medicine
  • Clinical chemistry and laboratory medicine
  • 2004
TLDR
The purpose of this review is to examine the current strategies in use for the therapeutic drug monitoring of immunosuppressant drugs and to discuss some of the factors that impinge on the monitoring of these drugs. Expand
Mycophenolate Mofetil
TLDR
Mycophenolate mofetil offers improved immunosuppressive therapy following renal and probably other solid organ transplantation and after 6 months, the rates of biopsy-proven rejection were significantly reduced in patients receiving MMF. Expand
Mycophenolic acid in patients with immune‐mediated inflammatory diseases: From humans to dogs
TLDR
Human clinical studies have shown MPA to be safe and effective and support its off-label administration for immune-mediated diseases such as lupus, myasthenia gravis and atopic dermatitis, and this review summarizes the available literature for MPA pharmacokinetics and pharmacodynamics. Expand
Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine.
TLDR
Mycophenolate mofetil is a new immunosuppressive drug, exhibiting its effect through inhibition of proliferation of T- and B-lymphocytes, and is an interesting candidate drug for many other, mainly auto-immune mediated diseases. Expand
The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials.
  • S. Husain, Nina Singh
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
TLDR
Recognition of the unique characteristics of these agents and the evolving spectrum of opportunistic infections has implications for the differential diagnosis, management, and prophylaxis of infections in organ transplant recipients in the modern immunosuppressive era. Expand
Mycophenolate Mofetil
TLDR
Mycophenolate mofetil appears to be an attractive new agent in the prevention of graft rejection in renal transplant recipients that has shown superior efficacy to azathioprine. Expand
New Antiproliferative Immunosuppressive Agents
TLDR
Advances in drug research, design, and development have allowed for the introduction of new agents that have greatly increased the number of immunosuppressive agents available for use in transplant recipients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety.
TLDR
It is believed that mycophenolic acid is an effective drug for the treatment of moderate to severe psoriasis and that the risks of its long-term administration are acceptable. Expand
THE EFFECT OF A NEW IMMUNOSUPPRESSIVE DRUG, BREQUINAR SODIUM, ON HEART, LIVER, AND KIDNEY ALLOGRAFT REJECTION IN THE RAT
TLDR
The immunosuppressive activity of BQR is highly effective in prolonging heart, liver, and kidney allograft survival in the rat and should be an important addition to a polytherapeutic approach in the treatment of organ graft rejection. Expand
Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism.
TLDR
It is concluded that mizoribine selectively inhibits guanine ribonucleotide formation in purified T cells, whereas the effect of 6MP appears to be more dependent on adenine rib onucleotide depletion. Expand
Lymphocyte‐Selective Antiproliferative and Immunosuppressive Effects of Mycophenolic Acid in Mice
TLDR
The observations show that MPA has lymphocyte‐selective anti‐proliferative effects in vivo and can inhibit both cell‐mediated and humoral immune responses without major side effects, and has advantages over currently used and recently identified immunosuppressive drugs. Expand
RS-61443--a new, potent immunosuppressive agent.
TLDR
Long-term administration of RS-61443 (20 mg/kg/day) did not cause nephrotoxicity, hematot toxicity, or hepatotoxicity, with the exception of a slight elevation of the alkaline phosphatase levels. Expand
RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1
TLDR
Preliminary evidence suggests that the drug prevents chronic rejection and was well tolerated in all dose groups, with only one adverse event possibly related to the drug (hemorrhagic gastritis). Expand
Effects of the new anti-lymphocytic peptide cyclosporin A in animals.
The fungus metabolite cyclosporin A is a small cyclic peptide acting as a novel antilymphocytic agent. It is effective following either parenteral or oral administration in mice, rats andExpand
Immunosuppressive effect of mycophenolic acid.
TLDR
Compared with other agents, mycophenolic acid is approximately equipotent to 6-mercaptopurine in immunosuppressive effect, determined by the decreases in the number of plaque forming cells and hemolysin titer. Expand
Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion
TLDR
It is suggested that MPA does not inhibit early responses of T and B lymphocytes lo mitogenic or antigenic stimulation but blocks the cells at the time of DNA synthesis, the cytostatic effect of MPA is more potent on lymphocytes than on other cell types, such as fibroblasts and endothelial cells. Expand
Antipurines and Purine Metabolism
The study of the involvement of purines in lymphocyte function has been highlighted by two dramatic and unrelated discoveries. The first, the discovery in 1958 that 6-mercaptopurine (6-MP) had markedExpand
...
1
2
3
4
5
...